title: A flow cytometry-based assay for screening FimH antagonists.
abstract: Urinary tract infections (UTIs), including cystitis and pyelonephritis, affect a large proportion of the population and account for significant medical costs. In more than 80% of UTIs, uropathogenic Escherichia coli (UPEC) is the causative pathogen. The initial step in the pathogenesis of the infection is the adherence of UPEC to the human bladder epithelium, enabling the invasion into the host cells and the development of UTIs. This process is mediated by the lectin FimH located on type I pili and enables UPECs to attach to oligomannosides of the glycoprotein uroplakin Ia presented on uroepithelial cells. FimH antagonists such as α-d-mannopyranosides have been shown to interfere with the attachment of UPEC to their host cells, thus providing a novel therapeutic opportunity for the treatment and prevention of UTIs. In this article, we report a flow cytometry-based assay to evaluate the potential of FimH antagonists for the prevention of the infection of the human urinary bladder cell line 5637 by UPEC strain UTI89. The assay was optimized and validated, and the inhibitory potency of different α-d-mannopyranosides was determined. Finally, the IC(50) values measured by the flow cytometry-based assay were compared with those reported for other assay formats.
authors.affiliation: Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, Basel, Switzerland.
authors.forename: Meike
authors.initials: M
authors.lastname: Scharenberg
authors.forename: Daniela
authors.initials: D
authors.lastname: Abgottspon
authors.forename: Evelin
authors.initials: E
authors.lastname: Cicek
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Jiang
authors.forename: Oliver
authors.initials: O
authors.lastname: Schwardt
authors.forename: Said
authors.initials: S
authors.lastname: Rabbani
authors.forename: Beat
authors.initials: B
authors.lastname: Ernst
mesh_terms: D018830:Adhesins, Escherichia coli / Q000378:metabolism*; D000818:Animals; D001667:Binding, Competitive; D045744:Cell Line, Tumor; D055808:Drug Discovery / Q000379:methods; D004353:Drug Evaluation, Preclinical; D004847:Epithelial Cells / Q000187:drug effects; D004903:Erythrocyte Aggregation / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D036781:Fimbriae Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005434:Flow Cytometry / Q000379:methods*; D006168:Guinea Pigs; D006801:Humans; D015151:Immunoblotting / Q000379:methods; D020128:Inhibitory Concentration 50; D008358:Mannose / Q000031:analogs & derivatives / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D015203:Reproducibility of Results; D001743:Urinary Bladder / Q000187:drug effects; D014551:Urinary Tract / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D056689:Uropathogenic Escherichia coli / Q000502:physiology*
chemical_list: D018830:Adhesins, Escherichia coli; C058769:fimH protein, E coli; D036781:Fimbriae Proteins; D008358:Mannose